28.06.2018 • NewsBASFDede WillamsEU

EU Probes BASF/Solvay Nylon Merger

EU Probes BASF/Solvay Nylon Merger (c) BASF
EU Probes BASF/Solvay Nylon Merger (c) BASF

The European Commission has opened an in-depth investigation into BASF’s proposed purchase of Solvay’s nylon (polyamide) business, saying the deal could reduce competition and lead to higher prices along the production chain. The EU regulatory body has until Oct. 31, 2018 to take a decision.

The German major announced last September that it had agreed to pay €1.6 billion for Solvay’s global integrated nylon operations, in a move aimed at boosting its access to markets in Asia and South America and gaining access to key raw material adiponitrile (ADN).

“We need to carefully assess whether the proposed acquisition would lead to higher prices or less choice for European businesses and, ultimately, consumers,” said the EU’s Competition Commissioner, Margrethe Vestager.

According to the EU regulatory body, the proposed transaction would create a company with a market size almost double that of the closest competitor. In addition, the merged entity would control substantial parts of the merchant markets along with production at all levels of the nylon chain.

Currently, Solvay is the only nylon producer in Europe that also makes the key intermediates, of which it sells a major portion to other nylon producers. BASF produces nylon intermediates, but not ADN, and uses nearly all its production internally.

Competitors raised fears during the Commission’s initial investigation that the merged group would stop supplying key products because of its own increased needs. These include ADN, hexamethylene diamine, adipic acid, hexamethylenediamine adipate salt, nylon 6.6 base polymer and nylon 6.6 engineering plastics.

In addition, the Commission noted that there is no indication that competition in the marketplace could be preserved by the entrance of new producers, since access to key feedstocks such as ADN is limited.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Virtual Event

Downstream Purification
Bioprocess Forum

Downstream Purification

Save the Date: November 21+25, 2025
Join leading scientists, process engineers, and biomanufacturing innovators for a two-day virtual event exploring the latest breakthroughs in downstream purification.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.